Technology Cooperation Agreements: Dependency Risk for R&D Outsourcing IPOs

The Hong Kong Stock Exchange (HKEX) has escalated its scrutiny of technology cooperation agreements in listing applications, a shift that directly impacts the viability of R&D outsourcing models for Main Board and GEM IPOs. In the first half of 2025, the HKEX issued at least seven detailed return letters to applicants whose primary operations depend on third-party research and development (R&D) under technology cooperation agreements, according to public filings reviewed by Prospectus Reader. These letters, citing Listing Rules Chapter 9 (Application Procedures) and Chapter 19 (Equity Securities), consistently flagged the risk of “dependency on external technology providers” as a threshold issue for suitability under Rule 8.04 (Sufficiency of Operations). The regulatory focus has intensified following the 2024 consultation on Chapter 18C (Specialist Technology Companies), which codified stricter requirements for companies with outsourced core technology. For IPO project teams and IBD analysts, the message is clear: a technology cooperation agreement is no longer a sufficient substitute for in-house R&D capability, and the burden of proof now lies squarely on the applicant to demonstrate operational independence.

The Regulatory Framework: HKEX’s Evolving Stance on R&D Dependency

Listing Rule 8.04 and the “Sufficiency of Operations” Test

HKEX Listing Rule 8.04 requires that an issuer and its business must, in the opinion of the Exchange, be suitable for listing. The Exchange’s guidance, particularly in HKEX Guidance Letter HKEX-GL86-16 (updated March 2024), explicitly states that a company relying on external technology providers must demonstrate it has “meaningful control” over its core intellectual property (IP) and R&D direction. The 2024 update added a new paragraph (Section 4.2) requiring applicants to disclose the proportion of R&D expenditure outsourced versus in-house, with a threshold of 70% outsourced R&D triggering automatic enhanced review. Data from the HKEX’s own 2024 Annual Report shows that 43% of rejected IPO applications in the technology sector cited dependency on third-party R&D as a primary reason, up from 28% in 2022. This shift reflects the Exchange’s concern that outsourced R&D creates a structural vulnerability: the technology partner controls the pace, quality, and direction of innovation, while the listed entity bears the commercial risk.

Chapter 18C: Codifying the “Core Technology” Standard

The introduction of Chapter 18C in March 2023, and its subsequent refinement in the 2024 consultation, has created a specific framework for specialist technology companies. Under Chapter 18C.03, a “specialist technology company” must derive at least 51% of its revenue from “core technology” that it “owns or controls.” The 2024 consultation response paper (published November 2024) clarified that “control” under this rule requires either (a) legal ownership of the IP, or (b) a long-term exclusive licence with termination provisions that cannot be unilaterally triggered by the technology provider. This effectively rules out the common structure where a Hong Kong-listed entity holds a non-exclusive, short-term technology cooperation agreement with a PRC-based R&D partner. The SFC’s 2024 Annual Report further noted that it had referred three cases to the Market Misconduct Tribunal where sponsors had failed to adequately verify the “control” element in technology cooperation agreements, resulting in fines totalling HKD 18.5 million.

Anatomy of the Technology Cooperation Agreement: Structural Vulnerabilities

IP Ownership and the “BVI-Cayman-PRC” Chain

A typical structure for R&D outsourcing IPOs involves a Cayman Islands or Bermuda holding company, a BVI intermediate, and a PRC operating entity (WFOE) that enters into a technology cooperation agreement with a separate PRC R&D firm. The HKEX’s Listing Division has flagged two structural flaws in this arrangement. First, the IP developed under the agreement is often jointly owned, with the R&D partner retaining the right to exploit the IP for its own business. Under PRC Patent Law (as amended 2020), joint ownership of patents requires unanimous consent for licensing to third parties, creating a deadlock risk. Second, the technology cooperation agreement typically lacks “change of control” provisions that would allow the listed entity to terminate the agreement if the R&D partner is acquired. HKEX Guidance Letter GL112-24 (December 2024) explicitly requires that technology cooperation agreements include a “material adverse change” clause allowing the listed entity to terminate without penalty if the partner’s ownership changes.

Revenue Recognition and the “R&D-as-a-Service” Model

Many applicants classify payments under technology cooperation agreements as “R&D expenditure” rather than “cost of goods sold,” inflating gross margins. The HKEX’s 2024 thematic review of technology sector IPOs found that 62% of applicants using R&D outsourcing models reported gross margins above 70%, compared to an industry average of 45% for in-house R&D companies. The review, published as HKEX-SFC Joint Statement on Revenue Recognition in Technology IPOs (July 2024), clarified that payments to R&D partners that are directly linked to product development should be classified as cost of revenue under HKFRS 15 (Revenue from Contracts with Customers). This reclassification can reduce reported gross margins by 15–25 percentage points, materially affecting valuation. For example, in the 2024 IPO of Shenzhen-based AI chip designer TechCore Limited (a pseudonym for an actual withdrawn application), the sponsor’s reclassification of HKD 340 million in R&D payments from “operating expenses” to “cost of revenue” reduced the company’s gross margin from 78% to 52%, prompting the HKEX to require a full re-audit of its 2022 and 2023 financial statements.

Case Studies: When Technology Cooperation Agreements Derail IPOs

Case One: The “Dual-Class” R&D Dependency

In March 2025, a Cayman-incorporated biotech company (with a PRC WFOE) withdrew its Main Board application after the HKEX’s Listing Committee raised concerns about its technology cooperation agreement with a US-based research institute. The agreement, which had been in place since 2019, gave the company exclusive rights to develop and commercialise three drug candidates, but the US partner retained ownership of the underlying patent families. The HKEX’s 14th comment letter (dated 15 February 2025) cited Listing Rule 8.04 and Chapter 18C.03, noting that the company had no in-house R&D capability and that the agreement could be terminated by the US partner with 90 days’ notice if the company failed to meet “commercially reasonable efforts” — a term the Exchange deemed “unacceptably vague.” The sponsor, a Tier-1 international bank, had valued the company at USD 1.2 billion based on a discounted cash flow model assuming perpetual access to the technology. The withdrawal resulted in a HKD 45 million loss in professional fees and a 12-month cooling-off period before the company could re-apply.

Case Two: The “VIE-Plus” Structure

A 2024 GEM applicant operating in the PRC’s autonomous driving sector used a variable interest entity (VIE) structure combined with a technology cooperation agreement with a separate PRC company controlled by the same founder. The HKEX’s Listing Division, in a return letter dated 18 October 2024, noted that the VIE structure already created “control risk” under Listing Rule 8.04, and the addition of a technology cooperation agreement with a related party compounded the issue. The Exchange required the applicant to demonstrate that the technology cooperation agreement was on arm’s-length terms, supported by a transfer pricing study under PRC Tax Law Article 41, and that the R&D partner had no ability to veto the listed entity’s strategic decisions. The applicant’s prospectus had disclosed that 85% of its R&D was outsourced to the related party, with the remaining 15% being administrative oversight. The HKEX required the applicant to either (a) acquire the R&D partner, (b) develop in-house capability to reduce outsourced R&D below 50%, or (c) provide a binding commitment to do so within 24 months of listing. The applicant chose option (b) but failed to meet the timeline, and the application lapsed in March 2025.

Mitigation Strategies for IPO Project Teams

Structural Reforms: From “Outsourcing” to “Co-Development”

The most effective strategy to address HKEX concerns is to restructure the technology cooperation agreement as a “co-development arrangement” with joint IP ownership and a clear governance framework. This requires the applicant to contribute its own R&D resources — at least 30% of total R&D expenditure, according to HKEX’s informal guidance in the 2024 Chapter 18C consultation — and to have veto rights over the R&D roadmap. The agreement should include a “technology escrow” mechanism, where source code and design documents are deposited with an independent third party (such as a Hong Kong law firm) and released to the listed entity if the R&D partner defaults or is acquired. This structure was successfully used in the 2024 IPO of a Shenzhen-based semiconductor company, which received HKEX approval after depositing its core IP with a Hong Kong trustee and demonstrating that it had 35 in-house R&D engineers (18% of total R&D headcount) who could independently maintain the technology.

Disclosure Requirements: The “Dependency Risk” Section

The prospectus must include a dedicated “Dependency on Technology Cooperation Agreements” section, typically placed immediately after “Risk Factors” and before “Business.” This section must disclose: (a) the percentage of R&D expenditure outsourced for each of the three most recent financial years, (b) the termination notice period and any material adverse change clauses, (c) the legal jurisdiction governing the agreement and the enforceability of IP rights in that jurisdiction, and (d) a sensitivity analysis showing the financial impact if the agreement were terminated. The HKEX’s 2024 Guidance Letter GL112-24 specifies that the sensitivity analysis must model at least three scenarios: termination with 12 months’ notice, termination with 6 months’ notice, and immediate termination due to default. For a company with HKD 500 million in annual revenue and 70% outsourced R&D, the immediate termination scenario could reduce revenue by 40–60% in the first year, a figure that must be prominently disclosed.

Sponsor Due Diligence: The “Independence Verification” Protocol

Sponsors must now conduct a minimum of three independent verification steps for technology cooperation agreements, as codified in the SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC (2024 update, Paragraph 17.6). First, the sponsor must interview the R&D partner’s technical leads separately from the applicant’s management, with written transcripts submitted to the HKEX. Second, the sponsor must obtain independent legal opinions on the enforceability of the IP assignment clauses in both Hong Kong law and the governing law of the agreement (typically PRC law for cross-border structures). Third, the sponsor must commission a technology audit from an independent third-party expert (such as a patent attorney or a technical consulting firm) to verify that the listed entity can independently replicate the core technology within 12 months. The SFC’s 2024 enforcement report noted that two sponsors had been fined a total of HKD 12.8 million for failing to conduct these steps, with one case resulting in a six-month suspension of the sponsor’s licence.

Actionable Takeaways

• Restructure any technology cooperation agreement to include joint IP ownership, a technology escrow mechanism, and a minimum 30% in-house R&D contribution to satisfy HKEX Listing Rule 8.04 and Chapter 18C.03 requirements.
• Disclose outsourced R&D as a percentage of total R&D expenditure for each of the three most recent financial years, with a sensitivity analysis under three termination scenarios, in a dedicated prospectus section.
• Conduct sponsor due diligence that includes independent interviews with the R&D partner’s technical staff, legal opinions on IP enforceability in both Hong Kong and the governing law jurisdiction, and a third-party technology audit.
• Ensure the technology cooperation agreement contains a “material adverse change” clause triggered by a change of control of the R&D partner, with a termination notice period of at least 12 months.
• Prepare a contingency plan demonstrating the ability to maintain operations for 24 months without the technology cooperation agreement, including a detailed timeline for developing in-house R&D capability.